Table 2 Demographics and clinical features of neonates with serotype III GBS invasive infections compared with those with other serotype GBS invasive infections
Clinical characteristics | Type III iGBS (n = 118) | Type Ia iGBS (n = 33) | Type Ib iGBS (n = 15) | Type V iGBS (n = 6) | Other iGBS (n = 10) |
|---|---|---|---|---|---|
Gestational age (weeks), median (IQR) | 39.0 (38.0–40.0) | 38.0 (37.0–39.0) | 37.0 (30.0–39.0)* | 35.5 (29.8–39.3)* | 37.0 (34.8–40.0) |
Birth body weight (g), median (IQR) | 3040 (2700–3350.0) | 2760 (2490–3085) | 3015 (1350–3165)* | 2248 (1586–2912)* | 2560 (2016–3138)* |
Gender, male/female n (%) | 77 (65.3)/41 (34.8) | 13 (39.4)/20 (60.6) | 8 (53.3)/7 (46.7) | 4 (66.7)/2 (33.3) | 5 (50.0)/ 5 (50.0) |
Onset of diseases (day), median (IQR) | 27.5 (14.8–53.3) | 30.0 (3.5–56.5) | 2.0 (1.0–30.0)* | 14.0 (1.0–21.3)* | 2.5 (1.0–11.8)* |
 Early-onset disease (≤ 7 days) | 14 (11.9) | 10 (30.3) | 10 (66.7)* | 2 (33.3) | 5 (50.0) |
 Late-onset disease (8–90 days) | 96 (81.4)* | 19 (57.6) | 2 (13.3) | 2 (33.3) | 2 (20.0) |
 Late late-onset disease (>  90 days) | 8 (6.8) | 4 (12.1) | 3 (20.0) | 2 (33.3) | 3 (30.0) |
Clinical manifestations | |||||
 Bacteremia | 115 (97.5) | 32 (97.0) | 15 (100) | 6 (100) | 10 (100) |
 Meningitis | 31 (26.3) | 13 (39.4) | 6 (40.0) | 0 (0) | 1 (10.0) |
 Pneumonia | 12 (10.2) | 2 (6.1) | 5 (33.3) | 0 (0) | 2 (20.0) |
 Septic shock | 8 (6.8) | 9 (27.3) | 7 (46.7)** | 3 (50.0)** | 4 (40.0)* |
 Respiratory failure | 8 (6.8) | 8 (24.2) | 9 (60.0)** | 4 (67.7)** | 4 (40.0)* |
 Multi-organ failure | 2 (1.7) | 3 (9.1) | 7 (46.7)** | 3 (50.0)** | 4 (40.0)* |
 Disseminated intravascular coagulopathy | 5 (4.2) | 4 (12.1) | 7 (46.7)** | 3 (50.0)** | 4 (40.0)* |
Treatment outcomes | |||||
 Complete cure without any sequelae at discharge | 104 (88.1) | 26 (78.8) | 8 (53.3)** | 3 (50.0)* | 7 (70.0) |
 Neurological complications | 15 (12.7) | 6 (18.2) | 2 (13.3) | 1 (16.7) | 5 (50.0)** |
 Mortality | 1 (0.8) | 3 (9.1) | 5 (33.3)** | 2 (33.3)** | 1 (10.0) |